ASCO 2022 Conference Coverage


 

ASCO 2022 Three-Year Outcomes and Correlative Analyses in Patients With NSCLC and a Very High PD-L1 Tumor Proportion Score ≥ 90% Treated With 1L Pembrolizumab

319 views
June 8, 2022
Comments 0
Login to view comments. Click here to Login